The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-world study with a large population

鼻咽癌 医学 肿瘤科 体积热力学 内科学 人口 小学(天文学) 放射科 环境卫生 放射治疗 物理 天文 量子力学
作者
Xiaohui Wang,Nan Huang,Pui Lam Yip,Jing Wang,Runda Huang,Zhuang Sun,Dehua Kang,Qian He,Xiaowu Deng,Chong Zhao,Melvin L.K. Chua,Fei Han
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:194: 110154-110154 被引量:5
标识
DOI:10.1016/j.radonc.2024.110154
摘要

Abstract

Background and purpose

The delineation of clinical target volume (CTV) for primary nasopharyngeal carcinoma (NPC) is currently controversial and the international guideline still recommend a uniform border for CTV regardless of the tumor extent. We conducted this prospective, real-world study to evaluate the clinical outcomes of our individualized CTV delineation method based on distance plus substructures.

Materials and Methods

We preliminarily investigated the local extension patterns of NPC on 354 newly diagnosed patients and defined the structures surrounding the nasopharynx as Level-1 to Level-4 substructures stratified by the risk of invasion. We then enrolled patients with newly diagnosed NPC without distant metastasis to investigate our individualized CTV delineation protocol. All patients received intensity modulated radiotherapy. CTV1 and CTV2 were prescribed doses of 60 Gy and 54 Gy in 30∼33 fractions. The primary endpoint was local recurrence-free survival (LRFS); secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. The local failure patterns were also analyzed.

Results

From January 2008 to December 2012 and from January 2013 to September 2019, 356 and 648 patients were enrolled, named as training set and validation set, respectively. With a median follow-up of 104.6 (interquartile, 73.1-126.9) and 51.4 (39.5-78.5) months, 31 (8.7%) and 38 (5.9%) patients in training and validation sets experienced local recurrence, and the 5-year LRFS was 93.0% and 93.2%, respectively; 63 (17.7%) and 39 (6%) patients died in training and validation sets, and the 5-year overall survival (OS) was 88.5% and 93.4%, respectively. For the whole study cohort (N=1004) with a median follow-up of 66.6 (41.5-98.0) months, the 5-year LRFS and OS was 93.2% and 91.5%. The grade 3 late toxicities included xerostomia, subcutaneous fibrosis, hearing impairment, trismus, visuality impairment and skin atrophy, with a total incidence of 1.5%. Sixty-seven of 69 (97.1%) local recurrence was in high-dose area.

Conclusion

Our individualized CTV delineation method can achieve favorable local tumor control and long-term survival outcomes with acceptable late toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎应助momo采纳,获得10
1秒前
hh完成签到 ,获得积分10
1秒前
大大完成签到 ,获得积分10
1秒前
1秒前
量子星尘发布了新的文献求助10
3秒前
YI发布了新的文献求助10
3秒前
Stardust完成签到 ,获得积分10
4秒前
zero发布了新的文献求助10
4秒前
共享精神应助果粒多采纳,获得10
5秒前
ali应助史念薇采纳,获得10
7秒前
9秒前
海城好人完成签到,获得积分10
9秒前
10秒前
默默完成签到,获得积分10
10秒前
维尼完成签到,获得积分20
10秒前
12秒前
文档发布了新的文献求助10
13秒前
13秒前
科目三应助Loik采纳,获得10
14秒前
15秒前
15秒前
17秒前
17秒前
果粒多发布了新的文献求助10
18秒前
20秒前
22秒前
李泽雄完成签到,获得积分10
23秒前
gsq发布了新的文献求助30
23秒前
momo发布了新的文献求助10
23秒前
wdy111应助学习鱼采纳,获得20
25秒前
25秒前
G哟X完成签到 ,获得积分10
26秒前
27秒前
科目三应助Zz采纳,获得10
28秒前
29秒前
zzzjh驳回了李健应助
29秒前
脑洞疼应助暴躁小龙采纳,获得10
31秒前
笑点低方盒完成签到,获得积分10
32秒前
归尘发布了新的文献求助10
32秒前
传奇3应助momo采纳,获得10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158